Fibrocell Science (FCSC) 3.87 $FCSC
Global Stem Cell Therapy Market Forecasts and Trends Report 2015-2020 - Cardiology, Oncology, Neurology, Diabetes, Orthopedics & Hematology
M2 - Thu Apr 23, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bvcjlr/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Global Market Forecast (2014-2020)" report to their offering. This report analyzes the global markets for Stem Cell Therapeutics. The report provides the standard and the tailored research methodology approach. The market overview offers in depth analysis for the regional and country level analysis, for instance North America (U.S., and Canada), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Stem Cell Therapy Market by Applications 5.1 Cardiology 5.2 Oncology 5.3 Neurology 5.4 Diabetes 5.5 Orthopedics 5.6 Hematology 6 Stem Cell Therapy Market by Therapy Type 6.1 Autologous Stem Cell Therapy 6.2 Allogenous Stem Cell Therapy 6.3 Syngenous Stem Cell Therapy 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Celgene Corporation - Fibrocell Science, Inc. - Medipost - Mesoblast Ltd. - Pharmicell - Stem Cell Technologies For more information visit http://www.researchandmarkets.com/research/bv...ll_therapy
FCSC: 3.87 (+0.12), CELGZ: 2.76 (-0.12)
Fibrocell Science to Present at World Orphan Drug Congress USA 2015
GlobeNewswire - Fri Apr 17, 7:05AM CDT
Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that John Maslowski, Vice President of Scientific Affairs, will present at the World Orphan Drug Congress USA 2015 at 2:30 p.m. EDT on Thursday, April 23 at the Washington D.C. Hilton. Mr. Maslowski's presentation will focus on FCX-007, Fibrocell's novel gene-therapy drug candidate for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a congenital, orphan skin disease caused by the deficiency of the protein collagen VII (COL7). FCX-007 is a gene-modified autologous fibroblast that encodes COL7 and is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology.
FCSC: 3.87 (+0.12), XON: 44.10 (-0.91)
Scar Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 11:30AM CDT
The report "Scar - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Scar. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available at http://www.rnrmarketresearch.com/scar-pipelin...eport.html.
DSCI: 8.09 (-0.31), FCSC: 3.87 (+0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT
TANH: 12.29 (+0.54), CCSC: 5.42 (-0.15), STMP: 66.23 (-0.77), HGSH: 3.28 (+0.05), FSNN: 4.24 (-0.18), ATRA: 59.89 (-4.13), KRFT: 87.57 (-0.81), LPTN: 2.23 (-0.01), IIJI: 8.39 (-0.15), KFX: 11.02 (-0.01), ESPR: 104.60 (-4.29), FCSC: 3.87 (+0.12), ORMP: 7.45 (+0.08), AFMD: 11.72 (+3.47), SEED: 1.77 (+0.16), CALA: 13.41 (-0.35), LIME: 2.83 (-0.06), VBLT: 4.23 (+0.07), APOL: 17.51 (-0.40), REPH: 11.88 (+1.04)
Fibrocell Science appoints Keith A. Goldan as SVP & CFO
M2 - Thu Mar 19, 6:11AM CDT
Cell therapy company Fibrocell Science (NasdaqCM:FCSC) said on Wednesday that Keith A. Goldan has been elected as its senior vice president and chief financial officer with immediate effect.
FCSC: 3.87 (+0.12)
New finance chief at Fibrocell
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:21PM CDT
FCSC: 3.87 (+0.12)
Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief Financial Officer
GlobeNewswire - Wed Mar 18, 3:05PM CDT
Fibrocell Science, Inc. (Nasdaq:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced the appointment of Keith A. Goldan as Senior Vice President and Chief Financial Officer (CFO), effective immediately. Mr. Goldan offers more than 20 years of executive finance and operational leadership in biopharmaceutical and medical technology companies.
FCSC: 3.87 (+0.12), XON: 44.10 (-0.91), TEVA: 64.41 (+1.16)
Fibrocell Science incurs lower basic net loss of USD0.08 per share Q4 2014
M2 - Mon Mar 16, 3:15AM CDT
Cell therapy company Fibrocell Science (Nasdaq:FCSC) stated on Friday that it recorded a basic net loss of USD0.08 per share for the fourth quarter ended 31 December 2014.
FCSC: 3.87 (+0.12)
Fibrocell Science's (FCSC) CEO David Pernock on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 13, 11:50AM CDT
FCSC: 3.87 (+0.12)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.33 (+0.01), ZIOP: 10.81 (-0.39), UNIS: 3.56 (-0.18), FCSC: 3.87 (+0.12), XON: 44.10 (-0.91), MNKD: 4.80 (-0.16)
Fibrocell Science reports 4Q loss
Automated Insights - Fri Mar 13, 7:37AM CDT
EXTON, Pa. (AP) _ Fibrocell Science Inc. (FCSC) on Friday reported a loss of $3.4 million in its fourth quarter.
FCSC: 3.87 (+0.12)
Fibrocell Science beats by $0.07, revenue in-line
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 7:15AM CDT
FCSC: 3.87 (+0.12)
Fibrocell Science Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
GlobeNewswire - Fri Mar 13, 7:10AM CDT
- Significant progress advancing gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB), a devastating and progressive orphan skin disease -
FCSC: 3.87 (+0.12), XON: 44.10 (-0.91)
Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 10, 12:41PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 6.89 (-0.71), ANY: 4.08 (-0.19), ASPS: 23.24 (+0.76), MARPS: 13.17 (+0.17), AKRX: 55.24 (-0.68), MIND: 4.80 (-0.16), LMIA: 11.77 (-0.06), ENPH: 13.47 (-0.43), FCSC: 3.87 (+0.12), ANTH: 5.20 (+0.31), ANAT: 101.35 (+0.58), TITN: 14.39 (-0.08), NNBR: 25.12 (-0.01), CLMT: 27.83 (+0.14)
Fibrocell Science (FCSC) in Focus: Stock Surges 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:11AM CST
Fibrocell Science, Inc. (FCSC) was a big mover last session, as the company saw its shares rise almost 11% on the day.
FCSC: 3.87 (+0.12), ANIP: 70.26 (-1.52)
Fibrocell up big after presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 3:07PM CST
FCSC: 3.87 (+0.12), XON: 44.10 (-0.91)
Global Stem Cell Therapy Market Forecasts and Trends Report 2015-2020 - Cardiology, Oncology, Neurology, Diabetes, Orthopedics & Hematology
M2 - Thu Apr 23, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bvcjlr/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Global Market Forecast (2014-2020)" report to their offering. This report analyzes the global markets for Stem Cell Therapeutics. The report provides the standard and the tailored research methodology approach. The market overview offers in depth analysis for the regional and country level analysis, for instance North America (U.S., and Canada), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Stem Cell Therapy Market by Applications 5.1 Cardiology 5.2 Oncology 5.3 Neurology 5.4 Diabetes 5.5 Orthopedics 5.6 Hematology 6 Stem Cell Therapy Market by Therapy Type 6.1 Autologous Stem Cell Therapy 6.2 Allogenous Stem Cell Therapy 6.3 Syngenous Stem Cell Therapy 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Celgene Corporation - Fibrocell Science, Inc. - Medipost - Mesoblast Ltd. - Pharmicell - Stem Cell Technologies For more information visit http://www.researchandmarkets.com/research/bv...ll_therapy
FCSC: 3.87 (+0.12), CELGZ: 2.76 (-0.12)
Fibrocell Science to Present at World Orphan Drug Congress USA 2015
GlobeNewswire - Fri Apr 17, 7:05AM CDT
Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that John Maslowski, Vice President of Scientific Affairs, will present at the World Orphan Drug Congress USA 2015 at 2:30 p.m. EDT on Thursday, April 23 at the Washington D.C. Hilton. Mr. Maslowski's presentation will focus on FCX-007, Fibrocell's novel gene-therapy drug candidate for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a congenital, orphan skin disease caused by the deficiency of the protein collagen VII (COL7). FCX-007 is a gene-modified autologous fibroblast that encodes COL7 and is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology.
FCSC: 3.87 (+0.12), XON: 44.10 (-0.91)
Scar Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 11:30AM CDT
The report "Scar - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Scar. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available at http://www.rnrmarketresearch.com/scar-pipelin...eport.html.
DSCI: 8.09 (-0.31), FCSC: 3.87 (+0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT
TANH: 12.29 (+0.54), CCSC: 5.42 (-0.15), STMP: 66.23 (-0.77), HGSH: 3.28 (+0.05), FSNN: 4.24 (-0.18), ATRA: 59.89 (-4.13), KRFT: 87.57 (-0.81), LPTN: 2.23 (-0.01), IIJI: 8.39 (-0.15), KFX: 11.02 (-0.01), ESPR: 104.60 (-4.29), FCSC: 3.87 (+0.12), ORMP: 7.45 (+0.08), AFMD: 11.72 (+3.47), SEED: 1.77 (+0.16), CALA: 13.41 (-0.35), LIME: 2.83 (-0.06), VBLT: 4.23 (+0.07), APOL: 17.51 (-0.40), REPH: 11.88 (+1.04)
Fibrocell Science appoints Keith A. Goldan as SVP & CFO
M2 - Thu Mar 19, 6:11AM CDT
Cell therapy company Fibrocell Science (NasdaqCM:FCSC) said on Wednesday that Keith A. Goldan has been elected as its senior vice president and chief financial officer with immediate effect.
FCSC: 3.87 (+0.12)
New finance chief at Fibrocell
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:21PM CDT
FCSC: 3.87 (+0.12)
Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief Financial Officer
GlobeNewswire - Wed Mar 18, 3:05PM CDT
Fibrocell Science, Inc. (Nasdaq:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced the appointment of Keith A. Goldan as Senior Vice President and Chief Financial Officer (CFO), effective immediately. Mr. Goldan offers more than 20 years of executive finance and operational leadership in biopharmaceutical and medical technology companies.
FCSC: 3.87 (+0.12), XON: 44.10 (-0.91), TEVA: 64.41 (+1.16)
Fibrocell Science incurs lower basic net loss of USD0.08 per share Q4 2014
M2 - Mon Mar 16, 3:15AM CDT
Cell therapy company Fibrocell Science (Nasdaq:FCSC) stated on Friday that it recorded a basic net loss of USD0.08 per share for the fourth quarter ended 31 December 2014.
FCSC: 3.87 (+0.12)
Fibrocell Science's (FCSC) CEO David Pernock on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 13, 11:50AM CDT
FCSC: 3.87 (+0.12)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.33 (+0.01), ZIOP: 10.81 (-0.39), UNIS: 3.56 (-0.18), FCSC: 3.87 (+0.12), XON: 44.10 (-0.91), MNKD: 4.80 (-0.16)
Fibrocell Science reports 4Q loss
Automated Insights - Fri Mar 13, 7:37AM CDT
EXTON, Pa. (AP) _ Fibrocell Science Inc. (FCSC) on Friday reported a loss of $3.4 million in its fourth quarter.
FCSC: 3.87 (+0.12)
Fibrocell Science beats by $0.07, revenue in-line
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 7:15AM CDT
FCSC: 3.87 (+0.12)
Fibrocell Science Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
GlobeNewswire - Fri Mar 13, 7:10AM CDT
- Significant progress advancing gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB), a devastating and progressive orphan skin disease -
FCSC: 3.87 (+0.12), XON: 44.10 (-0.91)
Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 10, 12:41PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 6.89 (-0.71), ANY: 4.08 (-0.19), ASPS: 23.24 (+0.76), MARPS: 13.17 (+0.17), AKRX: 55.24 (-0.68), MIND: 4.80 (-0.16), LMIA: 11.77 (-0.06), ENPH: 13.47 (-0.43), FCSC: 3.87 (+0.12), ANTH: 5.20 (+0.31), ANAT: 101.35 (+0.58), TITN: 14.39 (-0.08), NNBR: 25.12 (-0.01), CLMT: 27.83 (+0.14)
Fibrocell Science (FCSC) in Focus: Stock Surges 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:11AM CST
Fibrocell Science, Inc. (FCSC) was a big mover last session, as the company saw its shares rise almost 11% on the day.
FCSC: 3.87 (+0.12), ANIP: 70.26 (-1.52)
Fibrocell up big after presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 3:07PM CST
FCSC: 3.87 (+0.12), XON: 44.10 (-0.91)
